Related Experiment Video

Updated: Jul 17, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction.

J A de Lemos1, E M Antman, C M Gibson

  • 1Cardiovascular Division, Brigham and Women's Hospital, Boston Massachusetts, USA. jdelemos@rics.bwh.harvard.edu

Circulation
|January 25, 2000
PubMed

Insights

Combination therapy with abciximab and reduced-dose tissue plasminogen activator (tPA) significantly improves ST-segment resolution in ST-elevation myocardial infarction patients. This enhanced myocardial reperfusion may lead to better clinical outcomes and reduced mortality.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Myocardial Infarction Management

Background:

  • Patients with ST-elevation myocardial infarction (STEMI) and successful epicardial reperfusion but persistent ST elevation face high risks of death and left ventricular dysfunction.
  • The TIMI 14 trial demonstrated that combining abciximab with reduced-dose tissue plasminogen activator (tPA) enhances epicardial reperfusion speed and efficacy.

Purpose of the Study:

  • To evaluate if abciximab plus reduced-dose tPA offers additional benefits in myocardial reperfusion, specifically greater ST-segment resolution, compared to tPA alone in STEMI patients.

Main Methods:

  • A dose-ranging angiographic study (TIMI 14) involving 346 STEMI patients.
  • Patients received either tPA alone or combination therapy with abciximab plus reduced-dose tPA.
  • ST-segment resolution was assessed at 90 minutes post-treatment using 12-lead ECGs.

Main Results:

  • Combination therapy resulted in a 59% rate of complete ST resolution (>/=70%) at 90 minutes, versus 37% with tPA alone (P<0.0001).
  • Even among patients with TIMI 3 flow, combination therapy showed significantly higher complete ST resolution (69%) compared to tPA alone (44%) (P=0.0002).

Conclusions:

  • Combination therapy with abciximab and reduced-dose tPA improves myocardial reperfusion, indicated by greater ST-segment resolution, beyond epicardial flow restoration.
  • This enhanced microvascular reperfusion holds potential for improved clinical outcomes through increased myocardial salvage.
Abstract

More Related Videos

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...